Adaptive Biotechnologies: Funding, Investors & Team (Sep 2026)
Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.
Adaptive Biotechnologies has raised $125M across 2 funding rounds on record, the most recent a Post-IPO Debt of $125M announced in Sep 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Adaptive Biotechnologies Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Adaptive Biotechnologies Funding Rounds
Adaptive Biotechnologies raised $100k in a Post-IPO Equity announced in Mar 2022.
6 months later, a Post-IPO Debt of $125M was announced in Sep 2022.
Adaptive Biotechnologies Founders and Leadership Team
No contact details are on record for this team yet.
Adaptive Biotechnologies Funding Compared to Other Biotechnology Startups
Adaptive Biotechnologies' latest round of $125M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Adaptive Biotechnologies in Biotechnology and Seattle
Companies Similar to Adaptive Biotechnologies
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Adaptive Biotechnologies Funding FAQs
What does Adaptive Biotechnologies do?
Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.
How much funding has Adaptive Biotechnologies raised?
Adaptive Biotechnologies has raised $125M across 2 rounds on record. The most recent is a Post-IPO Debt of $125M announced in Sep 2022.
When did Adaptive Biotechnologies last raise funding?
Adaptive Biotechnologies' most recent funding round on record is a Post-IPO Debt of $125M, announced in Sep 2022.
Who founded Adaptive Biotechnologies?
FundedIQ lists Harlan Robins (Founder) at Adaptive Biotechnologies.
Who is the CEO of Adaptive Biotechnologies?
Chad Robins is listed as CEO at Adaptive Biotechnologies.
Where is Adaptive Biotechnologies headquartered?
Adaptive Biotechnologies is based in Seattle, Washington, United States.
How many employees does Adaptive Biotechnologies have?
Adaptive Biotechnologies is in the 501-1000 employee band.
How does Adaptive Biotechnologies' funding compare to other Biotechnology startups?
Adaptive Biotechnologies' latest round of $125M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Adaptive Biotechnologies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Adaptive Biotechnologies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.